Homocysteine and Heart Disease: Should You Be Tested?

Homocysteine is an amino acid your body produces during the metabolism of methionine. Elevated levels (hyperhomocysteinemia) have been associated with cardiovascular disease — but the picture is more nuanced than early headlines suggested.

Why it was first studied

Observational studies in the 1990s found that people with elevated homocysteine had higher rates of stroke and heart attack. Interpreting those signals correctly requires the same discipline used when reading any cardiovascular trial — see our guide to interpreting trial subgroup analyses for the framework clinicians actually apply.

What randomized trials revealed

Large trials of B-vitamin supplementation (folate, B6, B12) successfully lowered homocysteine but produced mixed results on hard cardiovascular endpoints. The strongest signal is for stroke reduction in folate-deficient populations. For a wider view of what is being tested in 2026, see our breakthrough cardiovascular clinical trials guide.

Who should consider testing?

• People with a personal or family history of premature cardiovascular disease.
• Patients with unexplained venous thromboembolism.
• Individuals with known MTHFR polymorphisms.
• Anyone whose blood pressure numbers and lipid profile already place them in an elevated 10-year risk band.

How to lower homocysteine if elevated

• Ensure adequate folate, B6, and B12 intake.
• Limit excessive coffee and alcohol.
• Maintain a healthy weight and stay physically active — start with the 2026 blood pressure categories chart to see where you stand today.

Bottom line

Homocysteine is a useful adjunct biomarker in select patients, but it is not a routine screen for everyone.